Akanda

Akanda EBITDA per Employee

The EBITDA per Employee of Akanda (AKAN) as of Oct 26, 2026 is -108,334.93 USD. In the previous year, EBITDA per Employee was -92,203.96 USD — a change of 17.49% (lower).

EBITDA per Employee

-108,334.93USD

YoY

17.49%

Last updated:

EBITDA per Employee of Akanda is 2025 -108,334.93 USD. EBITDA per Employee of Akanda was 2024 -92,203.96 USD. It decreases by 17.49% lower compared to the previous year.

The Akanda EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-19,592.07 USD
Jan 1, 2020
-36,213.80 USD
Jan 1, 2021
-55,861.98 USD
Jan 1, 2022
-360,393.26 USD
Jan 1, 2023
-125,384.20 USD
Jan 1, 2024
-92,203.96 USD
Jan 1, 2025
-108,334.93 USD
The Akanda EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-108,334.93USD+17.49%
-92,203.96USD-26.46%
-125,384.20USD-65.21%
-360,393.26USD+545.15%
-55,861.98USD+54.26%
-36,213.80USD+84.84%
-19,592.07USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

EBITDA per Employee of Akanda is -108,334.93 USD in 2025.

EBITDA per Employee of Akanda changed from -92,203.96 USD to -108,334.93 USD, representing a 17.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Akanda since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Akanda historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Akanda

All Key Metrics — Akanda